Transverse myelitis medical therapy
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis medical therapy |
|
Risk calculators and risk factors for Transverse myelitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- Transverse myelitis is a clinical syndrome with several possible causes; treatment should address the acute inflammatory spinal cord attack and, when identified, the underlying disease. A single maintenance regimen is not appropriate for every patient.
- A functionally important, presumed immune-mediated attack should be treated urgently after a compressive cause has been excluded. High-dose intravenous (IV) methylprednisolone is the usual initial therapy. Severe attacks and attacks with insufficient early recovery require prompt consideration of therapeutic plasma exchange (TPE).[1][2]
- Treatment should not be delayed while awaiting aquaporin-4 immunoglobulin G (AQP4-IgG) results when neuromyelitis optica spectrum disorder (NMOSD) is strongly suspected; current European guidance treats an NMOSD attack as a neurologic emergency.[2]
- Evidence for unclassified or idiopathic transverse myelitis remains limited. Recommendations for attack treatment and prevention of recurrence are therefore derived mainly from published consensus guidance for immune-mediated myelitis syndromes and from apheresis guidelines. The treatment plan should be reviewed as the etiology becomes clearer.
Medical Therapy
Acute immune therapy
| Therapy | Appropriate use | Practical guidance and limitations |
|---|---|---|
| High-dose IV methylprednisolone | Initial treatment for a functionally important presumed immune-mediated attack. | Contemporary NMOSD consensus specifies 1 gram IV once daily for 3–5 days. Response and adverse effects should be assessed daily. This regimen is the best-defined current consensus regimen for acute immune-mediated myelitis, but the dose and duration must be individualized when the cause remains unclassified.[1][2] |
| Oral corticosteroid taper | Selected patients after acute IV therapy, particularly when NMOSD or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is suspected or confirmed. | A taper is not automatically required for every unclassified or monophasic transverse-myelitis attack. NMOSD guidance permits a prolonged taper, sometimes for up to 3–6 months as a bridge to effective relapse-prevention therapy; MOGAD guidance also recommends an individualized taper. Duration should reflect etiology, severity, recovery, relapse risk, comorbidity, and the planned preventive treatment.[1][3] |
| Therapeutic plasma exchange (TPE) | Severe myelitis at presentation, rapid progression, major motor or autonomic deficit, or insufficient recovery within the first days of high-dose corticosteroid therapy. | Initiate early rather than waiting for completion of a prolonged steroid trial. In severe NMOSD myelitis, TPE may be used with corticosteroids or as first-line apheresis in selected patients. A typical course is approximately 5 procedures, daily or every other day; the number and exchanged volume are individualized by neurology and apheresis specialists.[1][4] |
| Immunoadsorption | Alternative apheresis technique when local expertise and access exist, principally for NMOSD-associated myelitis. | European consensus accepts immunoadsorption or TPE for NMOSD attacks, although experience and supporting evidence are greater for TPE.[1] |
| Intravenous immunoglobulin (IVIG) | Selected rescue therapy when response to IV methylprednisolone is insufficient and the clinical context, age, etiology, contraindications, or access makes IVIG preferable to apheresis. | IVIG is not an established routine first-line treatment for unclassified adult transverse myelitis. European pediatric MOGAD consensus considers IVIG or plasma exchange second-line after an insufficient response to IV methylprednisolone; evidence for IVIG in acute NMOSD is limited.[5][1] |
Pediatric considerations
- Treatment should be directed by a pediatric neurologist or neuroimmunologist. For pediatric MOGAD attacks, European consensus uses IV methylprednisolone 20–30 milligrams per kilogram per day (maximum 1 gram per day) for 3–5 days; IVIG or plasma exchange is used when the response is insufficient.[5]
- Adult prolonged-taper and apheresis protocols should not be copied to children without weight-, age-, and diagnosis-specific adjustment.
Cause-directed prevention of further myelitis attacks
| Clinical setting | Guideline-based approach |
|---|---|
| AQP4-IgG-positive NMOSD-associated transverse myelitis | Begin long-term relapse-prevention immunotherapy after the first confirmed attack. Current consensus favors an individualized monoclonal-antibody strategy selected from eculizumab or ravulizumab, inebilizumab, rituximab, or satralizumab, according to efficacy, safety, comorbidity, age, pregnancy plans, access, and patient preference. Azathioprine or mycophenolate mofetil may remain alternatives when targeted therapy is unsuitable or unavailable.[1][2] |
| MOGAD-associated transverse myelitis | Treat the acute attack with high-dose IV corticosteroids followed by an individualized oral taper. Long-term immunotherapy is not automatic after every first attack; it is considered particularly after relapse, with specialist-center input.[3][5] |
| Apparently monophasic or idiopathic transverse myelitis | Do not select indefinite immunotherapy solely from the syndromic label. Reassess the cause and recurrence risk during follow-up. Long-term immunotherapy requires a defined relapsing inflammatory disorder or another individualized specialist indication.[2][3] |
Symptom-directed pharmacotherapy
The following treatments relieve consequences of spinal-cord injury but do not treat the underlying inflammation.
| Problem | Medication approach |
|---|---|
| Neuropathic pain | After confirming a neuropathic pain phenotype, initial options include amitriptyline, duloxetine, gabapentin, or pregabalin. Select and titrate one agent according to comorbidity, interactions, sedation, renal function, pregnancy potential, and patient preference; review benefit and adverse effects regularly.[6] |
| Generalized spasticity or painful spasms | Use goal-directed treatment after identifying aggravating factors. Oral baclofen is commonly used for spasticity of spinal origin; tizanidine is an alternative when appropriate. Start at a low dose and titrate cautiously because excessive tone reduction, sedation, hypotension, or weakness can worsen mobility and transfers. Focal or refractory disabling spasticity warrants specialist spasticity assessment.[7] |
| Neurogenic urinary storage symptoms | After measurement of post-void residual urine and assessment of retention risk, an antimuscarinic agent may be used. A beta-3 adrenergic receptor agonist may be considered when antimuscarinic treatment is ineffective, contraindicated, or poorly tolerated. Treatment should be individualized and reviewed for cognitive, gastrointestinal, cardiovascular, and urinary adverse effects.[8][9] |
Monitoring and safety
- During high-dose corticosteroid therapy, monitor blood pressure, blood glucose, mental status, infection risk, fluid status, and gastrointestinal adverse effects. Assess the need for gastroprotection and venous-thromboembolism prophylaxis according to individual risk and local protocol.[1]
- During TPE or immunoadsorption, monitor vascular access, hemodynamics, blood count, coagulation parameters, fibrinogen, electrolytes, and treatment-related infection or bleeding risk.[4]
- Sequence IVIG and TPE with specialist input because subsequent plasma exchange may remove infused immunoglobulin.[4]
- Before long-term immunotherapy, complete agent-specific infection screening, vaccination planning, laboratory monitoring, pregnancy counseling when relevant, and shared decision-making.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Kümpfel T, Giglhuber K, Aktas O, et al.; Neuromyelitis Optica Study Group. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group. Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z. PMID: 37676297. Correction: Journal of Neurology. 2024;271(6):3702-3707. doi:10.1007/s00415-024-12288-2.
- ↑ 2.0 2.1 2.2 2.3 2.4 Giorgi L, Marignier R, Pique J, et al.; MIRCEM Network. French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder. Revue Neurologique (Paris). Published online July 21, 2026. doi:10.1016/j.neurol.2026.06.004. PMID: 42481362.
- ↑ 3.0 3.1 3.2 Giorgi L, Marignier R, Pique J, et al.; MIRCEM Network. French guidelines for the diagnosis and management of MOG antibody-associated disease. Revue Neurologique (Paris). 2025;181(7):597-607. doi:10.1016/j.neurol.2025.04.012. PMID: 40494723.
- ↑ 4.0 4.1 4.2 Zantek ND, Alquist CR, Hofmann JC, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the tenth special issue. Journal of Clinical Apheresis. 2026;41(Suppl 2):e70141. doi:10.1002/jca.70141. PMID: 42747330.
- ↑ 5.0 5.1 5.2 Bruijstens AL, Wendel EM, Lechner C, et al. European Union paediatric MOG consortium consensus: Part 5—Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology. 2020;29:41-53. doi:10.1016/j.ejpn.2020.10.005. PMID: 33176999.
- ↑ National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical guideline CG173. Published November 20, 2013; updated September 22, 2020. Accessed October 1, 2026.
- ↑ Verduzco-Gutierrez M, Raghavan P, Pruente J, et al. American Academy of Physical Medicine and Rehabilitation consensus guidance on spasticity assessment and management. PM&R. 2024;16(8):864-887. doi:10.1002/pmrj.13211. PMID: 38770827.
- ↑ Panicker JN, Fanciulli A, Krbot Skoric M, et al. European Academy of Neurology/European Federation of Autonomic Societies/International Neuro-Urology Society Guidelines for practising neurologists on the assessment and treatment of neurogenic urinary and sexual symptoms (NEUROGED Guidelines). European Journal of Neurology. 2025;32(4):e70119. doi:10.1111/ene.70119. PMID: 40208234.
- ↑ Ginsberg DA, Boone TB, Cameron AP, et al. The American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. The Journal of Urology. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239. PMID: 34495688.